CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The DEFINITIVE project seeks to validate the HER2DX test, a new diagnostic tool for optimizing treatment in early-stage HER2-positive breast cancer. By guiding therapy choices, it aims to reduce treatment toxicity, improve patient quality of life, and lower healthcare costs while maintaining effective outcomes.
HER2+ breast cancer affects around 390.000 women annually worldwide (i.e. 3 patients every 4 minutes).
Over the last decade, polychemotherapy and HER2-targeted therapies have improved patient´s survival; however, the reality is that most patients are cured with less intense, toxic, and costly drugs.
Up to now, no diagnostic test existed to guide the optimal therapy for each patient.
The 27-gene HER2DX test (TRL8) is a novel minimally invasive diagnostic tool which provides unprecedented predicti…
FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, Barcelona
Type: Research institute
Activity type: Research Organisations
SME: No
Spain, BARCELONA
Type: Research institute
Activity type: Research Organisations
SME: No
WSG WESTDEUTSCHE STUDIENGRUPPE GMBH
Germany, MONCHENGLADBACH
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
